Jul. 14 at 2:51 PM
$ZLAB Zai Lab Limited (NASDAQ: ZLAB), an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing transformative medicines, today announced the publication of new clinical data in The Lancet Oncology showcasing a significant breakthrough in the treatment of platinum-resistant ovarian cancer.
The study highlights a durable partial response and significant tumor regression in a Phase 2 trial participant treated with ZL-1310, Zai Lab’s novel, investigational ADC (antibody-drug conjugate) targeting folate receptor alpha.
“Patients with platinum-resistant ovarian cancer face limited treatment options and poor outcomes,” said Dr. Samantha Liu, Head of Oncology Clinical Development at Zai Lab. “These early results support the potential of ZL-1310 as a best-in-class targeted therapy, and we are accelerating efforts to advance this candidate into a pivotal Phase 3 study.”
